Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.42 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93812 | 0.98 | GAA (0.49) | GAACYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL5838840 | 0.86 | PHF8 (0.46) | LMNAPHF8KDM2AKDM7ADNM1 | |
| SCHEMBL22383271 | 0.85 | GAA (0.44) | GAACYP3A4CYP1A2CYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL27665152 | 0.84 | KDM5A (0.51) | LMNAPHF8DNM1ALDH1A1KMT2A | |
| SCHEMBL15468358 | 0.82 | CASP2 (0.53) | GAACYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL27665153 | 0.82 | KDM5A (0.53) | LMNAPHF8DNM1ALDH1A1KMT2A | |
| Stearic Acid SCHEMBL21245471 | 0.82 | DNM1 (0.64) | DNM1ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL12251401 | 0.81 | PHF8 (0.44) | GAAPHF8KDM2AKDM7ADNM1 | |
| SCHEMBL93986 | 0.81 | CYP1A2 (0.44) | GAACYP3A4CYP1A2CYP2D6LMNA | |
| SCHEMBL24626058 | 0.81 | CYP1A2 (0.46) | GAACYP3A4CYP1A2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344858-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALUMEND, LLC (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180344859-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALUMEND, LLC (US) | 2018-12-06 | — | — | US | disclosed |
| US-9884121-B2 | Biomaterials and a method for making and using same | ALUMEND, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-9855337-B2 | Biomaterials and a method for making and using the same | ALUMEND, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160175449-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALUMEND, LLC (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2114370-B1 | NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME | ALLERGAN INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8252771-B2 | A modified chitosan and a prostaglandin, prostamide, non-steroidal anti-inflammatory drug, or a corticosteroid; opthalmic drug delivery solution; improved bioavailability | ALLERGAN, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2425816-A2 | A pharmaceutical composition for use in treating an ocular disease or condition and a method for producing the composition | Allergan, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | disclosed |
| EP-2114370-A2 | NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME | Allergan, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080207561-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | ALLERGAN, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080200948-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | PHOTOBIOMED CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008094659-A2 | NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME | ALLERGAN, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1864972-A1 | BCRP/ABCG2 INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2007-12-12 | — | — | EP | disclosed |
| CN-1882548-A | pH-sensitive prodrugs of 2, 6-diisopropylphenol | AUSPEX PHARMACEUTICALS INC (US) | 2006-12-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200948-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | GAA 47/4885ACHE 42/4885CYP3A4 2344/4885 |
| US-20180344859-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | GAA 47/4885ACHE 42/4885CYP3A4 2344/4885 |
| US-20180344858-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | GAA 47/4885ACHE 42/4885CYP3A4 2344/4885 |
| US-20160175449-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | MMP1, PLOD3, MMP2 | GAA 47/4885ACHE 42/4885CYP3A4 2344/4885 |
| US-20080207561-A1 | NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME | PTGES, PTGES2, PTGIS | GAA 4656/4885ACHE 1146/4885CYP3A4 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.